Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (7002)	8/25/1999 1:36:00 AM
From: Vector1	Read Replies (1) \| Respond to of 9719

Rick, Great news!!! You the man. Once again the VD portfolio has benefited greatly from your insight and generosity. My kids (at least the ones that can talk) thank you for helping with their college educations. I invested a generous allocation to BTRN in their trust accounts at $2 per share. I am sad to say I have a much less generous allocation in my own PA. I can't be greedy however, it has been an incredible year so far. Lets hope it continues. V1

To: scaram(o)uche who wrote (7002)	8/25/1999 1:43:00 AM
From: Vector1	Read Replies (1) \| Respond to of 9719

Here is the WSJ article. Stock should fly tomorrow. 08/24 10:41P (WJ) WSJ(8/25):New BioTransplant System Is Used On Kidney Patient From The Wall Street Journal BOSTON -- Researchers at Massachusetts General Hospital, working with BioTransplant Inc., say that an unusual bone-marrow operation has allowed a kidney-transplant recipient to live for a year without immunosuppressive drugs. The drugs, which suppress the transplant recipient's tendency to reject the donated organ, are usually necessary for survival but carry serious side effects. Massachusetts General researchers, whose results are reported in the Aug. 27 issue of the journal Transplantation, used a type of bone-marrow transplant in which the donor marrow is blended with the patient's own marrow. The goal, since the bone marrow is the home base of the immune system, is to create a hybrid immune system that recognizes both transplants and the patient's own organs as belonging to the same body. In September, the patient received both kidney and bone-marrow transplants from her sister, and so far hasn't experienced rejection of either. The patient received the marrow transplant in part because it is a treatment for multiple myeloma, a cancer that caused her kidney problems. The research is still at an extremely early stage, but BioTransplant believes that the same system could be used for transplant patients with other types of cancers.